Please confirm that you would like to log out of Medscape.
If you log out, you will be required to enter your username and password the next time you visit.
Log outCancel
ESC 2019ENTRUST-AF PCI Supports Safety of Dual Therapy With EdoxabanENTRUST AF-PCI completes the trials of NOACs in patients with AF who undergo PCI, showing dual therapy with edoxaban was noninferior to vitamin K-antagonist–based triple therapy.
Medscape Medical News, September 2019
Fewer Patients Require 'Surgical Bailout' After TAVRTAVR carries a risk for complications that may necessitate conversion to open heart surgery, which carries high risk for mortality, but rates of 'surgical bailout' have decreased over time.
Medscape Medical News, September 2019
FDA Clears HeartFlow Planner Virtual Modeling Tool for CADThe HeartFlow Planner, used alongside the HeartFlow Analysis, allows interventional cardiologists to virtually model different clinical scenarios in real time, the company says.
FDA Approvals, September 2019
ESC 2019Long-Term Beta Blockers Post-CABG Questioned, Even With Low LVEFUse of guideline-recommended meds started out high after CABG but waned over time in a registry study that, controversially, also saw no survival benefit to long-term postoperative beta blockers.
Debating ISAR-REACT 5: Ticagrelor vs Prasugrel in ACSWhich P2Y12 inhibitor to use in patients with ACS? Rob Storey and ISAR investigator Dirk Sibbing debate ticagrelor vs prasugrel after the surprising results of the first head-to-head comparison trial.
theheart.org on Medscape, September 12, 2019
Are 30-Day Readmission Rules Deadly for Patients?A federal program aimed at lowering hospital readmissions has doctors divided on whether or not it is working -- and if it is actually harming patients.
Medscape Business of Medicine, September 3, 2019
ESC 2019When Guideline Authors Dismiss Important Studies Why does a guideline document on chronic coronary disease exclude the landmark ORBITA trial? Perhaps it's an existential tension, suggests John Mandrola, MD.
Seth Bilazarian Signs off from Clinical PracticeAfter more than 20 years, Dr Bilazarian decides to leave clinical practice and take a job in industry. He reflects on the reasons and his hopes for his new career.
ESC 2019Cardiologists Should Prescribe SGLT2 InhibitorsIs it fair to expect cardiologists to now prescribe the new diabetes drugs? Presentations at the European Society of Cardiology Congress prove persuasive to Melissa Walton-Shirley, MD.
